Edition:
United States

Genetic Technologies Ltd (GENE.OQ)

GENE.OQ on NASDAQ Stock Exchange Capital Market

1.09USD
21 Sep 2018
Change (% chg)

$-0.02 (-1.80%)
Prev Close
$1.11
Open
$1.11
Day's High
$1.12
Day's Low
$1.09
Volume
2,864
Avg. Vol
64,263
52-wk High
$2.05
52-wk Low
$0.75

Summary

Name Age Since Current Position

Paul Kasian

2018 Non-Executive Chairman of the Board, Acting Chief Executive Officer

Kevin Fischer

2016 Chief Financial Officer, Company Secretary

Mark Ostrowski

50 2014 President of Phenogen Sciences Inc

Richard Allman

53 2012 Scientific Director

M. Luisa Ashdown

57 2012 Director of Global Licensing and Intellectual Property

Susan Gross

2016 Senior Medical Director

Diana Newport

56 2013 Quality and Business Operations Director

Xue Lee

2018 Director

Jerzy Muchnicki

2018 Director

Peter Rubenstein

2018 Director

Lindsay Wakefield

2014 Non-Executive Independent Director

Biographies

Name Description

Paul Kasian

Dr. Paul Alexander Kasian is Non-Executive Chairman of the Board, Acting Chief Executive Officer of the Compamy. Dr. Kasian is an experienced executive director with demonstrated domestic and international success in funds management, encompassing senior leadership, investment and risk roles. Previously, Dr. Kasian has held senior leadership positions in a number of investment groups, including Chief Investment Officer at HSBC Asset Management; Head of HSBC Global Financial Team; Founding Director Accordius and Founding Director Wallara Asset Management. Dr. Kasian has funds management experience in Australia leading investment in the healthcare and life sciences sector. He was previously a Project Leader at ICI Australia providing advice on biotech projects and acquisitions. He holds a Doctorate in Philosophy in Microbiology and a Master of Business Administration, both from the University of Melbourne.

Kevin Fischer

Mr. Kevin Fischer is Chief Financial Officer, Company Secretary of the Company. With over ten years in senior finance roles with successful diagnostic companies, such as QIAGEN and Cellestis, Mr. Fischer is well qualified to take on the roles of CFO and joint Company Secretary. Mr. Fischer is a CPA and Chartered Secretary who has significant experience in the administration, financial management and reporting for international operations similar to those of Genetic Technologies.

Mark Ostrowski

Mr. Mark Ostrowski has been appointed as President of Phenogen Sciences Inc., the subsidiary of Genetic Technologies Ltd., effect from 25 November 2014. Mr. Ostrowski joined the Company in September 2012, and was appointed to the position of Senior VP Sales and Marketing. Mr Ostrowski possesses over 20 years of sales and marketing experience in molecular diagnostics having served in senior managerial positions at companies focused on women’s. health and oncology, including as Director of Sales Operations at Myriad Genetics (NASDAQ: MYGN) and Director of Managed Care Services at DIANON Systems (NASDAQ: DIAN). Prior to joining the Company, Mr. Ostrowski’s career spanned both early stage and established biomedical companies. During his tenure at Myriad, he had comprehensive exposure to all aspects of sales and marketing, managing a sales force of over 200 representatives, demonstrating average annual revenue growth of over 50%, and generating new strategic divisions and best practice policies.

Richard Allman

Dr. Richard Allman, Ph.D serves as a Scientific Director at Genetic Technologies Limited. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Prior to entering the biotech sector, Dr. Allman’s academic career encompassed oncology research, drug development, and assay design.

M. Luisa Ashdown

Ms. M. Luisa Ashdown serves as Director of Global Licensing and Intellectual Property at Genetic Technologies Limited. e has expertise in the area of genetics and immunology and has been with the Company since it started in 1989 during which time she was instrumental in the establishment of the Company’s laboratory capability and DNA testing services. She has since served in various roles including as Director of several of GTG’s subsidiaries. For over a decade, she has been involved in Licensing and Property defence and management.

Susan Gross

Dr. Susan J. Gross, M.D. is Senior Medical Director of the Company. She received her medical degree from the University of Toronto, Ontario, Canada, where she completed her residency in Obstetrics and Gynecology, as well as a fellowship in Maternal Fetal Medicine and a second residency/fellowship in Medical Genetics at the University of Tennessee (Memphis). She is board certified in both Obstetrics and Gynecology and Medical Genetics and is a Professor of Clinical Obstetrics & Gynecology, Women's Health, Pediatrics and Genetics at the Albert Einstein College of Medicine. She served as past division director for the Division of Reproductive Genetics at Montefiore Medical Center as well as Chairperson of the Department of Obstetrics and Gynecology and founder of the Human Genetics Laboratory at Jacobi Medical Center. Dr. Gross has spent decades not only in research and medical education, but also direct patient care, overseeing both large and small practice systems. She has worked on national and international guideline committees and lectured and published extensively on screening and genetic testing with a focus on new technologies and public health policy. She was previously the Chief Medical Officer of Natera Inc., a public genomic diagnostics company and is now President of SJG Advisors LLC, a company that provides comprehensive medical affairs and digital media expertise to the diagnostics industry.

Diana Newport

Ms. Diana Newport serves as a Quality and Business Operations Director at Genetic Technologies Limited in September 2013. She comes to the Company with extensive international Quality Systems and operational experience in the highly regulated industries of food and pharmaceutical. The Company will benefit from her experience gained from recent senior roles within the CSL quality control laboratories.

Xue Lee

Jerzy Muchnicki

Peter Rubenstein

Lindsay Wakefield

Dr. Lindsay Peter Wakefield is Non-Executive Independent Director of the Company. Dr. Wakefield started Safetech in 1985. In 1993, he left Medicine to become the fulltime CEO of the Company. Over the next 25 years Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged to become STS (Safetech Tieman Solutions) which is Australia’s largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Dr. Wakefield continues as Managing Director of STS and has been a keen Biotech investor for past 20 years, often at a mezzanine level.